Hebei Weimiao Biology Co., LTD 1
Location
  • Home
  • remdesivir cas1809249-37-3 manufacturers

Nov . 22, 2024 11:23 Back to list

remdesivir cas1809249-37-3 manufacturers



Remdesivir Manufacturers and Key Insights


Remdesivir, a nucleotide analog, has emerged as a critical antiviral medication in the fight against viral infections, particularly COVID-19. Identified by its CAS number 1809249-37-3, this drug was initially developed by Gilead Sciences for the treatment of hepatitis C and later studied for Ebola virus infections. In 2020, it gained prominence when it was granted emergency use authorization by various health authorities worldwide for the treatment of COVID-19.


Mechanism of Action

Remdesivir works by inhibiting viral RNA synthesis. It is converted into an active metabolite within the body that mimics adenosine triphosphate (ATP), thereby inserting itself into the viral RNA chain during replication. This incorporation ultimately results in premature termination of viral RNA synthesis, which hinders the virus's ability to replicate. Due to its efficacy in reducing the duration of symptoms in severe cases of COVID-19, the drug has become a cornerstone in the therapeutic management of this disease.


Key Manufacturers


Several manufacturers are involved in the production of Remdesivir, reflecting the global need for this essential medication during the pandemic and beyond. Gilead Sciences remains the primary producer of Remdesivir, instrumental not only in its development but also in the approval processes with regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).


In addition to Gilead, numerous generic manufacturing companies around the world have received licenses to produce Remdesivir. This is particularly relevant in low- and middle-income countries, where the need for affordable access to essential medications is paramount. Companies based in India, such as Hetero Labs and Cipla, have significantly scaled up their production capacities. They have been granted permissions under the World Health Organization's Emergency Use Listing (EUL) and have set pricing strategies that make the drug accessible to healthcare systems in these regions.


Regulatory Approvals


remdesivir cas1809249-37-3 manufacturers

remdesivir cas1809249-37-3 manufacturers

The path to regulatory approval for Remdesivir was expedited due to the global health crisis. Initial studies demonstrated a reduction in the recovery time for hospitalized COVID-19 patients, leading to its emergency use authorization in multiple countries from the onset of the pandemic. Subsequent randomized controlled trials reinforced its benefit in this cohort of patients, prompting further endorsements from health organizations.


In addition to its COVID-19 applications, ongoing research is assessing the drug's utility against other viral pathogens. The FDA approved the commercial use of Remdesivir in October 2020, firmly establishing its role in antiviral therapy.


Challenges and Considerations


Despite the advancements in production and distribution, challenges remain. The demand for Remdesivir surged during peak COVID-19 waves, leading to supply chain issues and potential shortages in some regions. Additionally, the drug is administered intravenously, which may limit its accessibility compared to oral antivirals.


There have also been considerations regarding the safety profile and the potential for adverse effects in certain patient populations. Ongoing pharmacovigilance is essential to monitor the long-term effects of Remdesivir therapy, especially in diverse demographic groups.


Conclusion


Remdesivir, with CAS number 1809249-37-3, has undeniably transformed antiviral treatment, especially in the context of COVID-19. The collaboration between innovative pharmaceutical companies and generic manufacturers is vital for ensuring global access to this critical medication. As we continue to navigate post-pandemic recovery and potential future outbreaks, the lessons learned from Remdesivir's rapid development and distribution will be invaluable in preparing for new challenges in public health.


Share
Next：

Latest news

If you are interested in our products, you can choose to leave your information here, and we will be in touch with you shortly.


Hit enter to search or ESC to close
en_USEnglish
afAfrikaans sqAlbanian amAmharic arArabic hyArmenian azAzerbaijani euBasque belBelarusian bn_BDBengali bs_BABosnian bg_BGBulgarian caCatalan cebCebuano zh_CNChina zh_TWChina (Taiwan) coCorsican hrCroatian cs_CZCzech da_DKDanish nl_NLDutch eoEsperanto etEstonian fiFinnish fr_FRFrench fyFrisian gl_ESGalician ka_GEGeorgian de_DEGerman elGreek guGujarati htHaitian Creole haHausa hawHawaiian he_ILHebrew hi_INHindi hmnMiao hu_HUHungarian is_ISIcelandic igIgbo id_IDIndonesian gaIrish it_ITItalian jaJapanese jvJavanese knKannada kkKazakh kmKhmer rwRwandese ko_KRKorean ckbKurdish kyKyrgyz loLao laLatin lvLatvian lt_LTLithuanian lbLuxembourgish mk_MKMacedonian mgMalgashi ms_MYMalay ml_INMalayalam mtMaltese miMaori mrMarathi mnMongolian my_MMMyanmar ne_NPNepali nb_NONorwegian nyNorwegian orOccitan psPashto fa_IRPersian pl_PLPolish pt_PTPortuguese pa_INPunjabi ro_RORomanian ru_RURussian smSamoan gdScottish Gaelic sr_RSSerbian stSesotho snShona sdSindhi si_LKSinhala sk_SKSlovak sl_SISlovenian soSomali es_ESSpanish suSundanese swSwahili sv_SESwedish tlTagalog tgTajik ta_INTamil tt_RUTatar teTelugu thThai tr_TRTurkish tkTurkmen ukUkrainian urUrdu ug_CNUighur uz_UZUzbek viVietnamese cyWelsh xhBantu yiYiddish yoYoruba zuZulu en_USEnglish